Trial Profile

An Open-Label, Single-Arm, Phase II Study of Pembrolizumab, Plinabulin Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Pembrolizumab (Primary) ; Plinabulin (Primary)
Indications Small cell lung cancer
Focus Proof of concept; Therapeutic Use

27 Mar 2025 According to a BeyondSpring Pharmaceuticals media release, Preliminary data from Phase 2 of Study 302 in 1L ES-SCLC is expected in second half of 2025.
11 Feb 2025 Planned primary completion date changed from 1 May 2025 to 1 Jun 2025.
25 Mar 2024 According to a BeyondSpring Pharmaceuticals media release, first patient has been dosed in this trial. This trial is being conducted in the Wuhan Union Hospital in China, with Dr. Xiaorong Dong as principal investigator.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com